Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

OncoVista Innovative Therapies

Request full access

Developing anticancer therapies by utilizing tumor-associated biomarkers

San Antonio, United StatesFounded 2004Biotech & Life Sciences

About OncoVista Innovative Therapies

OncoVista Innovative Therapies, Inc. operates as a biopharmaceutical firm focused on creating targeted anticancer treatments by leveraging tumor-associated biomarkers. Founded in September 2004 and based in San Antonio, Texas, the company aimed to develop therapies that were both more effective and less toxic for cancer patients. The former Chairman, CEO, and President was Alexander L. Weis, who guided the company's strategy to advance its drug candidates and seek new licensing or acquisition opportunities.

The company's business model centered on the development and eventual commercialization of its proprietary drug candidates. Its primary market was oncology, serving patients with specific types of cancer that could be identified through biomarkers. OncoVista's strategy involved progressing its compounds through clinical trials to gain regulatory approval, which would then generate revenue through drug sales or licensing agreements. The company's pipeline included two main drug candidates. The first, Cordycepin (OVI-123), was developed for refractory TdT positive leukemias and had been granted orphan drug status by the U.S. Food & Drug Administration. The second candidate, L-Nucleoside Conjugates (OVI-117), was a Thymidylate Synthase (TS) inhibitor intended for solid tumors such as colon, breast, and prostate cancer. OVI-117 was designed to offer enhanced pharmacological properties, retaining efficacy while reducing toxicity.

A significant milestone included the sale of its majority holding in its German subsidiary, AdnaGen AG, which provided funds to advance its clinical programs. The company also received FDA approval in 2012 to begin Phase I clinical trials for OVI-117. However, OncoVista faced challenges, including a three-year litigation case that was settled in 2015. By 2016, the company was reported as dormant following the resignation of its board of directors, which resulted in the license rights for OVI-117 returning to the licensor, Lipitek International, Inc.

Source: Dealroom company data

OncoVista Innovative Therapies in the San Antonio ecosystem

Live from Dealroom

The OncoVista Innovative Therapies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • Chicago Venture Partners
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about OncoVista Innovative Therapies on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See OncoVista Innovative Therapies on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.